...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Re: AHA 2018 Resverlogix Poster #2
7
Jul 18, 2018 12:14PM
6
Aug 29, 2018 12:53AM
1
Aug 29, 2018 09:14AM
8
Sep 23, 2018 07:43AM
1
Sep 29, 2018 11:37AM
4
Sep 30, 2018 03:29AM
3
Oct 08, 2018 11:54PM
4
Oct 16, 2018 03:21PM
2
Nov 05, 2018 12:40PM
3
Nov 05, 2018 12:56PM
2
Nov 05, 2018 01:03PM
4
Nov 09, 2018 09:11AM
1
Nov 09, 2018 11:43AM
1
Nov 12, 2018 10:23PM
2
Nov 13, 2018 03:23AM

"In a round about way is this Poster #2 saying that apabetalone has a positive affect on the mouse liver?"

That completely misses the point of the poster. You are referring to the data presented in panel 6 of the poster in which they investigated the ability of apabetalone to prevent the harmful effects of lipopolysaccharide (LPS)-induced endotoxemia on liver gene expression. In the abstract, they summarize these findings as "Acute endotoxemia is associated with activation of liver macrophages and endothelial cells and infiltration of immune cells. In mice exposed to 50 ug of LPS for 24h, apabetalone reduced liver mRNA marker expression for infiltrating monocytes, activated macrophages, and cellular adhesion (CD14, CCR2, ICAM and P-selectin)."

But that LPS liver data in panel 6 is only one small part of this poster. The other parts of the study investigate several facets of how apabetalone suppresses vascular inflammation and cell adhesion in endothelial cells and monocytes subjected to pro-inflammatory stimuli. Take another look at the abstract or poster to get the big picture.

BDAZ

3
Nov 13, 2018 12:24PM
Share
New Message
Please login to post a reply